Concentric By Ginkgo Has Entered Into A Co-Marketing Agreement With Illumina To Partner On Expanding Biosecurity Capabilities Globally
Portfolio Pulse from Benzinga Newsdesk
Concentric by Ginkgo, a unit of Ginkgo Bioworks (NYSE:DNA), has partnered with Illumina, Inc. (NASDAQ:ILMN) to expand global biosecurity capabilities. They plan to set up a pathogen monitoring network using Illumina's DNA sequencing technology. This 'bioradar' system will help detect and respond to biological threats, supporting global health objectives. The co-marketing agreement aims to enhance pathogen genomic surveillance and build local biosurveillance capacity, reducing reliance on third-party biosecurity services.
January 15, 2024 | 11:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ginkgo Bioworks' unit, Concentric, has entered a co-marketing agreement with Illumina to expand biosecurity capabilities globally, potentially increasing the demand for Ginkgo's services.
The partnership with Illumina could lead to increased demand for Ginkgo Bioworks' biosecurity services, as the agreement aims to expand the pathogen monitoring network. This could positively impact Ginkgo's revenue and market position in the short term.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Illumina has partnered with Concentric by Ginkgo to co-market and expand the use of its DNA sequencing technology in global biosecurity efforts, which may lead to increased utilization of its products.
The co-marketing agreement with Concentric by Ginkgo is likely to increase the exposure and use of Illumina's DNA sequencing technology in the biosecurity sector, which could have a positive short-term impact on sales and stock performance.
CONFIDENCE 75
IMPORTANCE 65
RELEVANCE 80